The effects of sacubitril/valsartan on heart failure with preserved ejection fraction: a meta-analysis

Jiao, Yuchen; Li, Yanyan; Zhang, Song; Zha, Yafang; Xiaowei, Meng; Zhang, Jiayan

doi:10.1080/00015385.2021.1963101

Cited by 4 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В нескольких метаанализах исследований сакубитрила / валсартана у пациентов с СНсФВ было установлено достоверное снижение частоты госпитализаций по поводу ХСН на 15-22%, но без значимого преимущества по влиянию на смертность (табл. 2) [16,[19][20][21].…”

Section: сердечная недостаточность с сохраненной и промежуточной фрак...unclassified

Efficacy of sacubitril / valsartan in the treatment of chronic heart failure: an updated review

Leonova

2023

Medicinskij sovet

View full text Add to dashboard Cite

Chronic heart failure (CHF) is currently a common disease and the search for new approaches to the treatment of various forms of CHF remains relevant. Sacubitril/valsartan is a member of a new class of angiotensin-neprilysin receptor inhibitors (ARNIs) that act on key neurohormonal mechanisms, including the RAAS and natriuretic peptides. Simultaneous inhibition of RAAS and neprilysin provides more effective neurohormonal modulation, preventing clinical deterioration in patients with CHF. New mechanisms of action of sacubitril/valsartan associated with the inhibition of several targets involved in cardiac hypertrophy, fibrosis, cardiac remodeling and apoptosis have been disclosed. Sacubitril/valsartan is recommended for CHF with low ejection fraction (EF) in addition to traditional therapy with ACE inhibitors, mineralocorticoid receptor antagonists, beta-blockers, and also has an independent effect. A number of studies have shown the effect of sacubitril/valsartan on heart remodeling, a decrease in the level of the NT-proBNP biomarker and an improvement in EF, and according to the PARADIGM-HF study, the drug significantly reduced the risk of cardiovascular mortality by 20% and hospitalizations for CHF by 21%, which found confirmation in three meta-analyses. The use of sacubitril/valsartan in CHF with preserved and intermediate EF showed a beneficial therapeutic effect and a decrease in the level of biomarkers, as well as a significant decrease in the frequency of hospitalizations due to CHF by 15–22%, but without a significant advantage in terms of the effect on mortality, which supported by several meta-analyses of studies. A number of large meta-analyses of studies of sacubitril/valsartan in CHF have shown reverse cardiac remodeling and a reduced risk of atrial fibrillation. Thus, the accumulated data substantiate and expand the possibilities of using sacu-bitril/valsartan in CHF.

show abstract

Section: сердечная недостаточность с сохраненной и промежуточной фрак...unclassified

Efficacy of sacubitril / valsartan in the treatment of chronic heart failure: an updated review

Leonova

2023

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

“…Even though S/V was connected to an increased risk of symptomatic hypotension, there were no signs of deteriorating renal function or hyperkalemia. Except for the hospitalization rate, in which the S/V treatment group favored HFpEF patients, the study found no differences between the two groups compared to valsartan or personalized medical therapy [ 111 ].…”

Section: Sacubitril/valsartan Therapymentioning

confidence: 99%

Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure

Iovanovici

Bungău

Vesa

et al. 2022

IJMS

View full text Add to dashboard Cite

Sacubitril/valsartan (S/V) is a pharmaceutical strategy that increases natriuretic peptide levels by inhibiting neprilysin and regulating the renin-angiotensin-aldosterone pathway, blocking AT1 receptors. The data for this innovative medication are mainly based on the PARADIGM-HF study, which included heart failure with reduced ejection fraction (HFrEF)-diagnosed patients and indicated a major improvement in morbidity and mortality when S/V is administrated compared to enalapril. A large part of the observed favorable results is related to significant reverse cardiac remodeling confirmed in two prospective trials, PROVE-HF and EVALUATE-HF. Furthermore, according to a subgroup analysis from the PARAGON-HF research, S/V shows benefits in HFrEF and in many subjects having preserved ejection fraction (HFpEF), which indicated a decrease in HF hospitalizations among those with a left ventricular ejection fraction (LVEF) < 57%. This review examines the proven benefits of S/V and highlights continuing research in treating individuals with varied HF characteristics. The article analyses published data regarding both the safeness and efficacy of S/V in patients with HF, including decreases in mortality and hospitalization, increased quality of life, and reversible heart remodeling. These benefits led to the HF guidelines recommendations updating and inclusion of S/V combinations a key component of HFrEF treatment.

show abstract

A journey in structural heart failure

Lancellotti

2023

Acta Cardiologica

View full text Add to dashboard Cite

The effects of sacubitril/valsartan on heart failure with preserved ejection fraction: a meta-analysis

Cited by 4 publications

References 39 publications

Efficacy of sacubitril / valsartan in the treatment of chronic heart failure: an updated review

Efficacy of sacubitril / valsartan in the treatment of chronic heart failure: an updated review

Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure

A journey in structural heart failure

Contact Info

Product

Resources

About